Abstract

Colorectal cancer (CRC) is the third highest mortality cancer in the United States and frequently metastasizes to liver and lung. Smad2 is a key element downstream of the TGF-β signaling pathway to regulate cancer metastasis by promoting epithelial to mesenchymal transition and maintaining the cancer stem cell (CSC) phenotype. In this study, we show that hsa-miR-140-5p directly targets Smad2 and overexpression of hsa-miR-140-5p in CRC cell lines decreases Smad2 expression levels, leading decreased cell invasion and proliferation, and increasing cell cycle arrest. Ectopic expression of hsa-miR-140-5p in colorectal CSCs inhibited CSC growth and sphere formation in vitro by disrupting autophagy. We have systematically identified targets of hsa-miR-140-5p involved in autophagy. Furthermore, overexpression of hsa-miR-140-5p in CSCs abolished tumor formation and metastasis in vivo. In addition, there is a progressive loss of hsa-miR-140-5p expression from normal colorectal mucosa to primary tumor tissues, with further reduction in liver metastatic tissues. Higher hsa-miR-140 expression is significantly correlated with better survival in stage III and IV colorectal cancer patients.The functional and clinical significance of hsa-miR-140-5p suggests that it is a key regulator in CRC progression and metastasis, and may have potential as a novel therapeutic molecule to treat CRC.

Highlights

  • Colorectal cancer (CRC) is one of the most common malignancies and causes 655,000 deaths per year worldwide [1]

  • It has been reported that hsa-miR-140-5p targets TGFBRI in hepatocellular carcinoma (HCC) and suppresses HCC growth and metastasis [30]

  • We show that Smad2 is the direct target of hsa-miR-140-5p and overexpression of hsa-miR-140-5p in CRC cell lines inhibited cell invasion (Figure 1)

Read more

Summary

Introduction

Colorectal cancer (CRC) is one of the most common malignancies and causes 655,000 deaths per year worldwide [1]. The most frequent sites of metastasis for CRC are liver and lung. Many early detection methods and therapeutic approaches have been explored, which have led to steady improvements in treating metastatic CRC over the last 20 years. The 5-year survival rate is still around 10% for the stage IV advanced stage colorectal cancer [2]. One of the major reasons for the failure of treating metastatic colorectal cancer is chemoresistance, and colorectal cancer stem cells (CSCs) are the key components of the resistance mechanism. In addition to resistance, increasing evidence suggests that tumor initiation and metastases are dependent on the small sub-population of CSCs [3]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call